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a therapeutic target, oncogenic KRAS has proven to be 'undruggable', and extensive efforts at developing specific anti-RAS agents have failed clinically (15, 16) . Alternative strategies, such as blockade of RAS effectors are being evaluated; yet there remains an urgent unmet need for more effective therapies.
In this regard, targeting the molecular chaperone heat shock protein 90 (Hsp90) represents a promising avenue for therapeutic intervention. Hsp90 is required for the stability and maturation of numerous key signal transduction proteins, termed 'client' proteins (17, 18) . Many of these clients play indispensable roles in cell growth and survival, and include such proteins as EGFR, RAF and AKT. Of note, cancer cells exploit the Hsp90 chaperone machinery as a biochemical buffer to protect a variety of mutated and/or overexpressed oncoproteins from targeted degradation, thereby facilitating aberrant cell survival and oncogene addiction (18, 19) . Importantly, inhibition of Hsp90 activity targets its clients for proteasomal destruction. Because of its coordinate and simultaneous impact on multiple signaling cascades, pharmacological blockade of Hsp90 can therefore overcome signaling redundancies and drug resistance mechanisms commonly seen in many cancers (20) (21) (22) . As such, Hsp90 has become an attractive molecular target for the development of novel anticancer agents.
Ganetespib (formerly STA-9090) is a small molecule inhibitor of Hsp90 with pharmacologic and biologic properties that distinguish it from other first-and second-generation inhibitors in terms of superior antitumor activity, potency and safety (23) . In addition, ganetespib is presently undergoing evaluation in multiple human clinical trials, including patients with advanced NSCLC.
Here we evaluated ganetespib activity in a panel of KRAS mutant NSCLC lines to determine the effects on signaling cascades responsible for KRAS-driven NSCLC cell survival. Further, we examined the potential combinatorial activity of ganetespib with clinical agents targeting key nodal components of these pathways as well as standard of care therapeutics for NSCLC. Taken together, the findings support a potential clinical utility for ganetespib in patients with KRAS mutant NSCLC. PI3K/mTOR inhibitors, A549, H2009, Calu-1 and H358 cells were treated with graded concentrations of ganetespib, AZD6244 or BEZ235 for 72 h and cell viability measured as above.
Western blotting
Following treatment, tumor cells were disrupted in lysis buffer (CST) on ice for 10 min. Lysates were clarified by centrifugation and equal amounts of proteins resolved by SDS-PAGE before transfer to nitrocellulose membranes (Invitrogen, Carlsbad CA). Membranes were immunoblotted with the indicated antibodies and antibody-antigen complexes visualized using an Odyssey system (LI-COR, Lincoln, NE).
In vivo tumor growth inhibition study
Female immunodeficient CD-1 (nude) mice (Charles River Laboratories, Wilmington, MA) were maintained in a pathogen-free environment, and all in vivo procedures were approved by the Synta Pharmaceuticals Corp. Institutional Animal Care and Use Committee. A549 NSCLC cells dextrose, 68.4% water) or p.o. dosed with BEZ235 formulated in PEG300/NMP (90% PEG300, 10% N-Methylpyrrolidone). Animals were treated with ganetespib at 50 mg/kg weekly or BEZ235 at 10 mg/kg 5 times a week, either alone or in combination. Tumor growth inhibition was determined as described previously (24) .
Multiple drug effect analysis
For combinatorial analysis, cells were seeded in 96-well plates at a predetermined, optimum growth density for 24 h prior to the addition of drug or vehicle to the culture medium. Drug combinations were applied at a non-constant ratio over a range of concentrations for 72 or 96
hours. For each compound tested, a 7 point dose range was generated based on 1.5 fold serial dilutions using IC 50 values set as the mid-point. Cell viability was assessed by either alamarBlue (Invitrogen, Carlsbad, CA) or CellTiter-Glo assays and normalized to vehicle controls. For each combination study, the level of growth inhibition (fraction affected) is plotted relative to vehicle control. Data are presented as one relevant combination point and the corresponding single agent data for each cell line tested.
Reverse phase protein array analysis
For single-agent ganetespib profiling, H2009, A549, H538 and Calu-1 cells were treated with DMSO (control) or ganetespib (250 nM) for 24 h. In the combination experiments, A549 cells were treated with ganetespib (25 nM) or BEZ235 (20 nM), either alone or in combination for 24 h.
Lysates were then prepared as recommended by the Reverse Phase Protein Analysis Core Facility at MD Anderson Cancer Center (Houston, TX). Serial diluted lysates were arrayed on nitrocellulose-coated FAST slides (Whatman) and probed for a standard list of antibodies as previously described (25, 26 
Results

Loss of viability and client protein expression by ganetespib in KRAS mutant NSCLC cells
The cytotoxic activity of ganetespib was initially evaluated in a panel of 20 NSCLC cell lines selected for expression of known KRAS mutations, including G12, G13 and G61 variants ( Table   1 ). Ganetespib potently reduced viability in all lines examined, with IC 50 values in the low nanomolar range. Representative viability curves for two lines, H727 and H441, are shown in Fig. 2A (left panels) . The IC 50 values for these G12V mutant KRAS-expressing cells were 28 and 14 nM, respectively. KRAS itself is not a client protein of Hsp90 and was therefore unaffected by ganetespib treatment (Supplementary Table S1 ). However, since targeted degradation of client proteins is a feature of Hsp90 inhibition, we examined expression changes in client and signaling pathway proteins associated with NSCLC progression. In H727 and H441 cells, ganetespib treatment resulted in a robust and dose-dependent decrease in EGFR and MET receptors, both established Hsp90 clients ( Fig. 2A, right panels) . The KRAS substrate C-RAF was potently destabilized in both cell lines and, as expected, only a relatively modest reduction in B-RAF protein levels was observed in H441 cells. Targeted degradation of these signaling intermediates was accompanied by inactivation of downstream effectors (p-MEK, p-ERK, p-AKT) and induction of apoptotic markers (cleaved PARP, increased BIM levels). AKT activation involves the phosphorylation of two residues: serine 473 (Ser473) and threonine 308 (Thr308). Of note, phosphorylation of Thr308 has been correlated with activity in NSCLC cells (27) and p-AKT (Thr308) expression was acutely sensitive to ganetespib treatment in H727 cells. Potent destabilization of p-AKT (Ser473) was seen in both lines. Interestingly, mammalian target of rapamycin (mTOR) signaling was affected by ganetespib in H441 cells, as evidenced by a reduction in levels of phosphorylated 4E-BP1 protein, a direct substrate of the mTOR-1 complex (mTORC1). Since AKT Ser473 is regulated by mTOR complex-2 (mTORC2) (28) , these data suggest that Hsp90 inhibition may coordinately impact cross-talk between the mTOR pathway and other KRAS-driven signaling cascades. We have previously reported that even brief exposure of NSCLC lines to ganetespib in vitro results in sustained activity and potent effects on cellular viability (23) . Therefore we exposed A549 and H2030 cells to graded concentrations of ganetespib for 1 h, and then investigated the effects on client protein pathways at 24 h. Doses were determined empirically for each line, using the minimal concentrations required for client protein depletion. For comparison, we included a continuous 24 h exposure to ganetespib at the lowest relative dose ( 
Multimodal suppression of oncogenic signaling by ganetespib confers superior cytotoxic activity over selective MEK and PI3K/mTOR inhibitors
Recent preclinical studies have provided a convincing rationale for the combinatorial use of targeted MEK and PI3K/AKT inhibitors in NSCLC, particularly in KRAS-driven lung tumors (29, 30) . Accordingly, here we focused on AZD6244, an allosteric inhibitor of the MEK1/2 kinases, and BEZ235, a dual pan-PI3K and mTOR inhibitor, both of which are under clinical development.
When the single-agent cell killing activity of these compounds was compared to that of ganetespib in a subset of mutant KRAS NSCLC lines (Fig. 3A) , ganetespib was typically more potent at reducing cell viability than either agent. AZD6244, in particular, was largely ineffective as a monotherapy, with IC 50 values ≥ 1000 nM in the four lines examined. We next examined modulation of the cellular signaling cascades targeted by these agents using Western blot analysis (Fig. 3B ). As expected, MEK blockade by AZD6244 resulted in consequent loss of downstream ERK activity with no observed effects on upstream (B-RAF or C-RAF), AKT or mTOR signaling. However, in all of the lines, AZD6244 induced a significant accumulation of phosphorylated MEK protein, indicating that treatment with this inhibitor resulted in the activation of a feedback signaling loop. Induction of feedback signaling was also observed in each of the four lines following exposure to the PI3K/mTOR inhibitor BEZ235 (Fig. 3B) . Consistent with its targeted activity, BEZ235 significantly suppressed p-AKT levels and completely abrogated mTOR activity, including complete loss of phosphorylated 4E-BP1 protein. Unexpectedly, BEZ235 treatment also increased p-MEK levels and this was associated with a robust up-regulation of activated (i.e. phosphorylated) ERK expression (Fig. 3B) . Therefore, despite direct effects on their molecular targets, both kinase inhibitors triggered compensatory signaling activity within the tumor cells.
In contrast, ganetespib treatment resulted in loss of C-RAF, p-MEK, p-ERK, total/p-AKT (and partial suppression of 4E-BP1 activity) across all lines, and without concomitant upregulation of feedback signaling (Fig. 3B ). In agreement with the cytotoxicity profiles shown in Fig. 3A , ganetespib treatment additionally manifested the highest pro-apoptotic activity, as shown by consistent elevations in cleaved PARP expression. These findings were supported by a more extensive reverse phase protein array analysis of ganetespib exposure in the same cell panel (Supplementary Table S1 ). Besides leading to the expected downregulation of client protein receptors (including EGFR, MET and HER2) and signaling intermediates of pathways regulated by these oncogenic drivers (Src, STAT3, GSK3), ganetespib treatment also selectively altered the expression of a number of proteins involved in mTOR signaling (S6, 4E-BP1, PDK1), cell cycle regulation and apoptosis. Taken together, these coordinate impacts on multiple signaling cascades conferred by Hsp90 chaperone inhibition underlies the superior therapeutic utility of ganetespib in KRAS mutant lung cancer lines.
Ganetespib suppresses feedback pathway activation and enhances the activity of MEK and PI3K/mTOR inhibitors in vitro
To extend these observations, we subsequently tested ganetespib in combination with inhibitors of MEK and PI3K/mTOR. Concurrent administration of low (IC 50 or IC 20 ) doses of ganetespib with AZD6244 substantially increased cell death in A549 and H2009 cells (Fig. 4A ). This effect was not universal, however, as no additional benefit was seen in the Calu-1 or H358 lines when the drugs were combined at similar ratios (Fig. 4A) . At the molecular level, single agent ganetespib robustly inhibited the C-RAF/MEK/ERK signaling axis in A549 and H2009 cells (Fig. 4B ).
AZD6244 treatment alone reduced downstream p-ERK expression, yet induced p-MEK accumulation in both cell types, consistent with the data shown in Figure 3B . Importantly, cotreatment with ganetespib blocked this effect, suggesting that the feedback loop(s) responsible for promoting signaling redundancy in these NSCLC cell lines were sensitive to Hsp90 inhibition.
In agreement with the cytotoxicity data (Fig. 4A) , the increased PARP cleavage observed in H2009 cells highlights the more potent pro-apoptotic activity seen with the ganetespib-AZD6244 combination.
Combinatorial benefit was also observed in five mutant KRAS NSCLC lines when ganetespib was dosed in combination with BEZ235 (Fig. 4C) . Selecting two of these lines, we found that single agent treatment of A549 and H2030 cells with either BEZ235 or another mTOR inhibitor, AZD8055, inhibited phosphorylation of 4E-BP1 as well as AKT (Ser473); thus mTOR activation was effectively abrogated in these cells (Fig. 4D) . However, cellular exposure to both mTOR inhibitors induced feedback pathway activation, again evidenced by an accumulation of p-MEK and p-ERK protein levels. Concurrent administration of ganetespib effectively suppressed this response in both lines (Fig. 4D) . Of note, ganetespib treatment also suppressed feedback signaling induced by both AZD6244 and BEZ235 in Calu-1 and H358 cells (Supplementary Fig.   S1 ). Calu-1 cells showed enhanced antiproliferative activity for the ganetespib + BEZ235 combination but not for ganetespib + AZD6244, and H358 cells were a line in which no benefit 
was observed for ganetespib with either inhibitor. Thus, while targeted Hsp90 inhibition could overcome compensatory signaling loops in mutant KRAS NSCLC lines, this effect was not the sole determinant of the improved therapeutic activity conferred by ganetespib treatment.
To examine potential mechanisms underlying the enhanced cytotoxicity seen with ganetespib + BEZ235 treatment, we performed reverse phase protein array analysis using A549 cells treated with IC 30 concentrations of each agent either alone or in combination ( Table 2 ). Consistent with its mTOR inhibitory activity, BEZ235 exposure caused a ≥6.8-fold reduction in phosphorylated S6 protein levels, and robust decreases in p70S6K and phospho-4E-BP1. Single agent effects of ganetespib on these mTOR signaling intermediates were comparatively moderate. Notably, combination treatment promoted greater cellular loss of these proteins, suggesting that mTOR signaling represents a point of convergence between the two agents. Unexpectedly this assay also identified Y-box protein 1 (YB-1), a translational repressor and AKT substrate, as a potential molecular effector linked to the pro-apoptotic response. YB1 protein levels were unaffected by either compound, and only a minor reduction in phosphorylated YB-1 was seen following ganetespib exposure. However, when the two drugs were combined, a greater than 1.4-fold loss of YB-1 expression was observed. Increased BIM levels confirmed apoptotic induction by the combination ( Table 2 ).
The antitumor efficacy of ganetespib is potentiated by PI3K/mTOR inhibition in a KRAS mutant xenograft model in vivo
To evaluate whether the combinatorial benefits on cell viability observed in vitro translated to improved efficacy in vivo, mice bearing A549 xenografts were treated with ganetespib and BEZ235, both as single agents and in combination. We have previously determined that the highest non-severely toxic dose (HNSTD) of ganetespib on a weekly dosing regimen is 150 mg/kg (23) . As shown in value 56%). Consistent with the in vitro findings above, concurrent treatment with both drugs at the same dose levels resulted in a significant enhancement of antitumor activity, inhibiting tumor growth by 79%. Combination treatment was well tolerated, with no significant loss of body weight seen after 3 weeks of dosing (data not shown). We also investigated the combination of ganetespib with AZD6244 (3 mg/kg, 5x/week) in the same model, however no significant improvement in efficacy over ganetespib alone was observed on this dosing regimen ( Supplementary Fig. S2 ).
Ganetespib sensitizes mutant KRAS NSCLC cells to standard of care chemotherapeutics
Finally, we examined the potential for improved therapeutic benefit by combining ganetespib with standard of care agents used in the clinical treatment of lung cancer. These included chemotherapeutics of the antimitotic, antimetabolite, topoisomerase inhibitor and alkylating agent classes (Fig. 6) . Combinatorial benefit was cell line specific; for example, in some lines ganetespib potentiated the cytotoxic effects of docetaxel (Fig. 6A ), in agreement with an earlier study (31) . When ganetespib was combined with either pemetrexed or gemcitabine enhanced cell killing was seen in H2030 and H2009 cells (Figs. 6B,C) . Synergistic effects, most notably in the H2030 line, were also seen when the topoisomerase inhibitors camptothecin and SN-38 were used as co-treatment with ganetespib (Figs. 6D,E) . Combinatorial benefit was also seen in Calu-1 cells when ganetespib was used in combination with either oxaliplatin or cisplatin (Fig. 6F) . These findings indicate that, depending on the cellular context, ganetespib may enhance the anticancer activity of conventional chemotherapies. was more sensitive to destabilization by ganetespib in KRAS mutant NSCLC lines than B-RAF, consistent with the observation that wild type B-RAF is not dependent on Hsp90 for stability (36) .
While this result reflects differing sensitivities of individual client proteins to Hsp90 inhibition (37) , it may additionally have important implications for lung cancer. Two elegant studies have recently provided convincing evidence that C-RAF, but not B-RAF, is essential for the initiation and development of KRAS-driven NSCLC using transgenic mouse models (38, 39) . Therefore, the potent degradation and loss of C-RAF protein afforded by ganetespib treatment provides an effective means to uncouple aberrant KRAS signaling from downstream MEK and ERK activation in NSCLC cells, and likely contributes to the antiproliferative activity of the compound.
With low nanomolar potency, ganetespib was cytotoxic to all mutant KRAS-bearing cell lines and even a brief exposure (1 h) was sufficient to negatively impact Hsp90 activity, highlighting the durable response property of the drug. At the molecular level, Hsp90 inhibition by ganetespib resulted in blockade of the PI3K/AKT/mTOR signaling axis, which mediates pro-survival signaling downstream of mutant KRAS. Importantly, a feature of Hsp90 inhibition is the capacity to simultaneously block multiple growth and survival pathways and concomitant inhibition of the PI3K/AKT/mTOR and RAF/MEK/ERK effector pathways represents an intrinsically intuitive strategy to counteract oncogenic KRAS activity. Indeed this approach has previously been explored using drug combinations. For example, Meng and colleagues (29) have shown that dual agent combination therapy using AZD6244 and the AKT inhibitor MK2206 resulted in synergistic effects on cell viability in vitro as well as tumor growth in KRAS-driven NSCLC tumors in vivo. Our data revealed that ganetespib was more potent than AZD6244 in reducing viability when each agent was used as a monotherapy, and combinatorial benefit was seen when the two compounds were used together in the A549 and H2009 cell lines. In another report, significant synergy in shrinking KRAS-driven lung tumors was observed when BEZ235 was combined with the MEK inhibitor ARRY-142886 (30), further supporting the potential benefit of coordinate blockade of the mitogenic and survival pathways activated by KRAS mutation. When ganetespib was used in combination with BEZ235, we observed superior cytotoxic activity in a greater number of KRAS universal response suggests that Hsp90 inhibition may provide a means to overcome adaptive resistance to targeted agents, and this possibility is currently under investigation.
Finally, we showed that ganetespib sensitized mutant KRAS cell lines to standard of care therapeutics currently in clinical use for NSCLC treatment. Again, benefit was not observed in all lines, further highlighting the complexity of treating this particular subset of cancer patients. It is reasonable to suggest that the heterogeneous response may simply reflect the cellular context, additional mutational status and/or signaling redundancies present within the cell lines. Overall, however, the ability of ganetespib to potentiate the cytotoxic effects of chemotherapeutic agents in the KRAS mutant setting provides a strong rationale for combinatorial approaches as a potentially useful therapeutic strategy. In this regard, we and others have previously shown that Hsp90 inhibition potentiates the activity of taxanes in preclinical NSCLC models (31, 47, 48) .
Perhaps more importantly, from our ongoing Phase 2b/3 GALAXY trial, comparing standard-ofcare docetaxel to the combination of ganetespib plus docetaxel in the second-line advanced NSCLC treatment setting, we have observed encouraging activity with ganetespib in the mutant KRAS population. Taken together, the data we are presenting here suggest that ganetespib may offer considerable promise for patients suffering from these generally untreatable cancers. 
